A very interesting time for #ADPKD ! It's especially exciting to see a large trial on #SGLT2 inhibitors now underway for ADPKD patients — a group not included in previous studies.
1
0
0
0
Hashtag
#sglt2
Advertisement · 728 × 90
🧵 (4/6)
The study focuses on #dapagliflozin, an #SGLT2 inhibitor already widely used in other kidney diseases. People with ADPKD have previously been excluded from trials with this class of medication.
0
0
1
0
🧵 (4/6)
The study focuses on #dapagliflozin, an #SGLT2 inhibitor already widely used in other kidney diseases. People with ADPKD have previously been excluded from trials with this class of medication.
0
0
0
0
📣 New Podcast! "The Science Behind SGLT2 Inhibitors — And When to Use Them with Dr. Renee Rucinsky" on @Spreaker #cat #diabetes #endocrine #environment #feline #medicine #sglt2 #veterinary
0
0
0
0
Four graphs show cumulative incidence differences between users of Sodium-Glucose Cotransporter 2 Inhibitors and all other patients. X axes represent follow-up time in months, y axes show cumulative incidence difference in %. The graphs depict outcomes for different conditions.
Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/41ApOb2
0
0
0
0
Sodium-glucose cotransporter 2 (#SGLT2) inhibitors were associated with significantly lower 12-month all-cause mortality, hospitalization, and kidney outcomes in patients with heart failure due to transthyretin amyloidosis (#ATTR) or light-chain amyloidosis (#AL).
Learn more: https://bit.ly/4bvoOLt
1
1
0
0
Metabolic diseases are rising rapidly across the US and Europe, with over 90% of healthcare professionals reporting high prevalence.
Read the full case study:
www.sperresearch.com/Case-Studies...
#Healthcare #MetabolicDiseases #DiabetesCare #Obesity #GLP1 #SGLT2 #PharmaInsights #MarketResearch
1
0
0
0
Figure 2. Graphs show the cumulative incidence of primary outcomes, comparing SGLT2i and GLP-1RA treatments for chronic kidney disease (A) and acute kidney injury (B). The X-axis represents time since initiation in years, and the Y-axis is cumulative incidence in % or MCC.
Initiation of #SGLT2 inhibitor therapy was associated with lower 5-year risk of chronic kidney disease and fewer acute kidney injuries vs #GLP-1 receptor agonists among individuals with #Type2Diabetes. ja.ma/4l128FZ
1
1
0
0
A DIABETES DRUG JUST REVERSED CHROMOSOMAL AGING
As a medical school professor, I teach that telomeres -- the protective caps on your chromosomes -- only shorten ... medicalxpress.com/news/2025-09-popular-dia...
#Telomeres #SGLT2 #MetabolicHealth #Longevity #AntiAging
0
0
0
0
In a move that could help people with Type 2 diabetes, NICE has recommended that they be offered a type of medicine called an SGLT-2 inhibitor, known as flozins, much earlier in their treatment.
healthcaretoday.com/article/new-...
#Healthcare #Type2Diabetes #SGLT2 #Medicine #Innovation
0
0
0
0
#MedNews - #SGLT2 inhibitors are linked to lower kidney, cardiovascular, and hepatic risks than #DPP4 inhibitors in patients with type 2 diabetes and liver cirrhosis.
Full story 👉 buff.ly/OT68EkO
#T2D
1
0
0
0
Four graphs compare DPP4 inhibitor and SGLT2 inhibitor effects over time. Graph A, 'ESKD,' shows cumulative incidence. Graph B, 'AKI,' shows similar data. Graph C, 'MACE,' shows a higher cumulative incidence. Graph D shows cumulative incidence of hepatic decompensation events. In all, gray test: P <.001.
Among adults with #Type2Diabetes and liver cirrhosis, #SGLT2 inhibitor use was associated with lower risks of end-stage kidney disease, cardiovascular events, mortality, and hepatic decompensation compared with DPP4 inhibitors.
ja.ma/4rxjZql
0
0
0
0
The March issue is now online!
👉 Read our latest articles!
onlinelibrary.wiley.com/toc/13652796/2026/299/3
#genetherapy #epilepsy #alzheimers #Porphyromonas #granulomatosis #polyangiitis #lungdisease #acetaminophen #thromboembolism #liver #cirrhosis #xenotransplantation #statins #SGLT2
0
0
0
0
#MedNews - #SGLT2 inhibitors may offer greater protection against acute and chronic kidney outcomes than #GLP1 receptor agonists in people with #Type2Diabetes.
Full story 👉 buff.ly/FLzNy5t
#T2D
0
0
0
0
Sodium Glucose cotransporter-2 drug protects kidneys and #cardiovascular #health [via MDI Labs] 🧪🥼⚕️❤️🩺
"treatment also preserved communication between different #kidney cell types and reduced age-associated inflammatory signaling"
mdibl.org/press-releas...
#SGLT2 #medicine #diabetes #inflammation
6
1
0
0
Figure 2 shows cumulative incidence of primary outcomes: Chronic kidney disease & Acute kidney injury. Both graphs plot SGLT2i & GLP-1RA over time. The number at risk for each is listed below each graph, with SGLT2i consistently having a higher number.
Initiation of #SGLT2 inhibitor therapy was associated with lower 5-year risk of chronic kidney disease and fewer acute kidney injuries vs #GLP-1 receptor agonists among individuals with #Type2Diabetes. ja.ma/4qLMErw
2
0
0
0
Two graphs show cumulative incidence of primary outcomes for chronic kidney disease (A) and acute kidney injury (B). SGLT2i (orange line) and GLP-1RA (blue line) are compared over time since initiation, y. Numbers at risk are noted.
Initiation of #SGLT2 inhibitor therapy was associated with lower 5-year risk of chronic kidney disease and fewer acute kidney injuries vs #GLP-1 receptor agonists among individuals with #Type2Diabetes. ja.ma/4adyhGg
2
0
0
0
#SGLT2 inhibitors: a new frontier in #thyroid function regulation?
Examine the current experimental and clinical observations and plausible, but still speculative, mechanisms by which SGLT2 inhibitors might influence thyroid function.
👉 buff.ly/a6AxZ9H
#EndoSky
0
0
0
0
Could combination therapy with #SGLT2 inhibitors and #GLP1 receptor agonists be used to address residual CV risk in people with #T2D, and who should be prioritized for such treatment?
Find out more 👉 buff.ly/dSRUAJE
#CardioSky
1
0
0
0
Figure 3. Number of events prevented/caused per 1000 patients treated with SGLT2 inhibitor for 1 year by diabetes status and level of albuminuria. The graph shows Urine albumin to creatinine ratio <200 mg/g & >=200 mg/g with/without diabetes.
#SGLT2 inhibitors reduced kidney disease progression, hospitalizations, and mortality in #CKD, regardless of #diabetes status or albuminuria level, supporting broader use in clinical guidelines.
ja.ma/4sQrcTl
4
1
0
1
Figure 2 shows cumulative incidence of primary outcomes: chronic kidney disease (A) and acute kidney injury (B). Both charts compare SGLT2i and GLP-1RA over 5 years, with increasing incidence over time. Numbers at risk are shown for each.
Initiation of #SGLT2 inhibitor therapy was associated with lower 5-year risk of chronic kidney disease and fewer acute kidney injuries vs #GLP-1 receptor agonists among individuals with #Type2Diabetes. ja.ma/4roN8Ur
1
0
0
0
#GLP1 #SGLT2 As these diabetes 2 & help well with weight loss circulatory, heart system Brain on addiction, compulsion plus. Getting cheaper. Pill forms, RX Data, bad effects. Future recommend for most population. Prevention, less illness lower health costs, fitter folks? Need 2 try search.app/iQSmi
0
0
0
0
Cover of JAMA, Journal of the American Medical Association, January 20, 2026, Volume 335, Number 3. Features research articles, opinions, and clinical reviews including "Effects of Sodium Glucose" and "World AIDS Day-At a Crossroads". Text: "This Week's Issue of JAMA".
📌 Editor’s Choice from this week's issue of JAMA:
➡️ Peripheral Neuropathy Review,
➡️ #SGLT2 Inhibitors and Kidney Outcomes,
➡️ Coronary Computed Tomography Angiography, and more.
ja.ma/4eRp9GH
2
0
0
0
An editorial from JAMA, published online November 7, 2025, titled "Time for Broader Adoption of SGLT2 Inhibitors in Clinical Practice?" by L. Parker Gregg, Biykem Bozkurt, and Sankar D. Navaneethan, discussing SGLT2 inhibitors for kidney and cardiovascular risk reduction.
💬 Editorial: #SGLT2 inhibitor treatment benefits extend to people with CKD and low albuminuria, as well as those with advanced #KidneyDisease, supporting wider use.
ja.ma/3NsEMfE
4
2
0
1
Four graphs display events prevented or caused per 1000 patients treated with a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor for 1 Year by Diabetes Status and Level of Albuminuria. The graphs show variance for diabetes vs. no diabetes.
Meta-analysis: #SGLT2 inhibitors slow kidney decline consistently across CKD severity and albuminuria range, supporting their routine use for kidney health.
ja.ma/4pNzTve
5
2
1
0
New insights into the cardio-renal benefits of SGLT-2 inhibitors and the coordinated role of the miR-30 family.
#SGLT2 #CardioRenal #MicroRNA #KidneyHealth #NephrologyResearch
www.sciencedirect.com/science/arti...
0
0
0
0
Die #Rhabdomyolyse ist eine gefürchtete, aber sehr seltene Nebenwirkung von Statinen. Medikamenteninteraktionen können das Risiko erhöhen. Mit #SGLT2-Inhibitoren scheint dies nicht der Fall zu sein – die Ko-Therapie könnte das Risiko sogar senken. (nach Reg.)
0
0
0
0
Four plots show cumulative incidence difference over time. Plot A shows time to ADT failure, B time to NHA failure, C disease-specific survival, and D overall survival. Each plot shows follow-up time in months on the x-axis and cumulative incidence difference on the y-axis.
Among men with #ProstateCancer undergoing hormone therapy, #SGLT2 inhibitor use was associated with lower risk of treatment failure and delayed progression compared with nonuse, supporting potential adjunctive benefit. ja.ma/4jzyDtZ
0
0
0
0
New Research Letter to read! Risk of #rhabdomyolysis with concomitant use of #statins and #SGLT2 inhibitors.
🔗 doi.org/10.1111/joim.70062
0
0
0
0
Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes: An Umbrella Review
Liu, H. et al.
Paper
Details
#SGLT2 #Type2Diabetes #UmbrellaReview
0
0
0
0